Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Greenworks
301260
5
Tuoxin Pharmaceutical Group
301089
(Q3)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow | ||||||||||
Goods sale service render cash | 3.71%214.23M | -30.21%1B | -34.89%702.77M | -37.64%448.25M | -42.15%206.57M | -15.56%1.44B | -5.88%1.08B | 10.97%718.77M | 28.99%357.1M | -3.78%1.7B |
Cash received relating to other operating activities | 87.57%4.96M | -20.30%15.81M | -57.15%12.82M | -59.11%8.11M | -76.67%2.64M | 28.04%19.84M | 118.86%29.91M | 806.52%19.84M | 669.46%11.33M | -3.68%15.5M |
Cash inflows from operating activities | 4.77%219.19M | -30.08%1.02B | -35.49%715.58M | -38.21%456.36M | -43.21%209.22M | -15.17%1.46B | -4.41%1.11B | 13.65%738.61M | 32.38%368.43M | -3.78%1.72B |
Goods services cash paid | 17.23%250.14M | -28.91%878.46M | -32.62%647.63M | -35.82%416.26M | -37.31%213.37M | -17.70%1.24B | -6.21%961.23M | 11.48%648.59M | 15.22%340.33M | -0.99%1.5B |
Staff behalf paid | -3.06%34.53M | -4.75%110.42M | -4.92%85.08M | -0.18%59.8M | 20.32%35.62M | -0.35%115.93M | 0.59%89.48M | -6.15%59.91M | -24.89%29.61M | -16.15%116.33M |
All taxes paid | -27.03%2.65M | -14.69%10.61M | -38.25%9.1M | -45.74%6.02M | -41.20%3.63M | -41.42%12.44M | -5.35%14.73M | 28.43%11.09M | -8.69%6.18M | -22.86%21.23M |
Cash paid relating to other operating activities | -13.65%20.76M | 7.95%49.13M | -6.26%51.03M | -1.02%34.53M | 10.33%24.04M | 37.81%45.51M | 116.84%54.43M | 109.63%34.89M | 15.10%21.79M | -35.61%33.02M |
Cash outflows from operating activities | 11.36%308.09M | -25.61%1.05B | -29.20%792.83M | -31.53%516.61M | -30.47%276.67M | -15.70%1.41B | -3.00%1.12B | 12.45%754.48M | 10.38%397.91M | -3.58%1.67B |
Net cash flows from operating activities | -31.79%-88.89M | -167.14%-30.85M | -629.13%-77.25M | -279.59%-60.24M | -128.78%-67.45M | 5.07%45.94M | -277.99%-10.59M | 24.43%-15.87M | 64.13%-29.48M | -11.12%43.73M |
Investing cash flow | ||||||||||
Net cash received from disposal of fix assets、 intangible assets 、other long-term asset | -99.97%1.6K | 51.25%4.96M | 29,159.58%4.73M | 29,157.72%4.73M | 29,439.85%4.73M | 20.47%3.28M | 159.35%16.16K | 159.35%16.16K | 5,782.35%16K | 2,526.18%2.72M |
Cash inflows from investing activities | -99.97%1.6K | 51.25%4.96M | 29,159.58%4.73M | 29,157.72%4.73M | 29,439.85%4.73M | 20.47%3.28M | 159.35%16.16K | 159.35%16.16K | 5,782.35%16K | 2,526.18%2.72M |
Cash paid to acquire fixed assets intangible assets and other long-term assets | -23.34%24.27M | -30.73%88.98M | -7.38%73.82M | 29.66%55.24M | 4.03%31.67M | 13.02%128.45M | -10.63%79.7M | -33.93%42.6M | 108.30%30.44M | 12.79%113.64M |
Cash outflows from investing activities | -23.34%24.27M | -30.73%88.98M | -7.38%73.82M | 29.66%55.24M | 4.03%31.67M | 13.02%128.45M | -10.63%79.7M | -33.93%42.6M | 108.30%30.44M | 12.79%113.64M |
Net cash flows from investing activities | 9.90%-24.27M | 32.88%-84.01M | 13.29%-69.09M | -18.61%-50.51M | 11.45%-26.94M | -12.84%-125.16M | 10.64%-79.68M | 33.95%-42.58M | -108.19%-30.43M | -10.20%-110.92M |
Financing cash flow | ||||||||||
Cash received from capital contributions | ---- | --0 | ---- | ---- | ---- | --344.26M | --344.26M | --344.26M | --344.26M | --0 |
Cash from borrowing | --69.44M | --86.85M | --34.25M | --23.85M | ---- | ---- | ---- | ---- | ---- | --90.16M |
Cash inflows from financing activities | --69.44M | -74.77%86.85M | -90.05%34.25M | -93.07%23.85M | ---- | 281.84%344.26M | 299.56%344.26M | 381.29%344.26M | 1,421.67%344.26M | --90.16M |
Borrowing repayment | ---- | -35.26%10.2M | -52.60%5.21M | -52.60%5.21M | ---- | --15.75M | --11M | --11M | ---- | --0 |
Dividend interest payment | 93.54%1.54M | -29.09%23.06M | -30.40%22.01M | -31.81%20.97M | -18.12%795.52K | 1,137.74%32.52M | 1,826.08%31.63M | 3,856.88%30.76M | 1,087.38%971.55K | -78.77%2.63M |
Cash payments relating to other financing activities | ---- | -97.87%371.64K | -97.79%371.64K | -97.72%371.64K | ---- | 5,579.28%17.48M | 5,482.65%16.78M | 5,448.75%16.28M | ---- | -66.96%307.78K |
Cash outflows from financing activities | 93.54%1.54M | -48.86%33.63M | -53.54%27.6M | -54.24%26.56M | -18.12%795.52K | 2,140.08%65.75M | 2,958.16%59.41M | 5,320.49%58.04M | 1,087.38%971.55K | -95.44%2.94M |
Net cash flows from financing activities | 8,635.10%67.9M | -80.89%53.22M | -97.66%6.66M | -100.95%-2.7M | -100.23%-795.52K | 219.31%278.51M | 238.24%284.85M | 306.23%286.22M | 1,422.88%343.29M | 235.63%87.22M |
Net cash flow | ||||||||||
Net increase in cash and cash equivalents | 52.44%-45.27M | -130.93%-61.63M | -171.78%-139.68M | -149.81%-113.46M | -133.59%-95.19M | 895.02%199.29M | 19,353.99%194.58M | 1,617.04%227.77M | 481.59%283.38M | 117.30%20.03M |
Add:Begin period cash and cash equivalents | -17.76%285.38M | 134.91%347.01M | 134.91%347.01M | 134.91%347.01M | 134.91%347.01M | 15.68%147.72M | 15.68%147.72M | 15.68%147.72M | 15.68%147.72M | -47.55%127.69M |
End period cash equivalent | -4.65%240.11M | -17.76%285.38M | -39.43%207.33M | -37.80%233.55M | -41.59%251.82M | 134.91%347.01M | 165.98%342.3M | 233.24%375.49M | 706.85%431.1M | 15.68%147.72M |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
Audit Opinions | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion |
Auditor | -- | Zhonghui Certified Public Accountants (Special General Partnership) | -- | -- | -- | Zhonghui Certified Public Accountants (Special General Partnership) | -- | -- | -- | Zhonghui Certified Public Accountants (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.